{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:10:36Z","timestamp":1792681836060,"version":"4.5.0"},"reference-count":150,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.leukres.2010.04.016","type":"journal-article","created":{"date-parts":[[2010,6,8]],"date-time":"2010-06-08T08:38:08Z","timestamp":1275986288000},"page":"1255-1268","source":"Crossref","is-referenced-by-count":263,"title":["BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review"],"prefix":"10.1016","volume":"34","author":[{"given":"Xin","family":"An","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit K.","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Rong","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Charles R.","family":"Ashby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2010.04.016_bib1","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.hoc.2004.03.011","article-title":"Natural history and staging of chronic myelogenous leukemia","volume":"18","author":"Cortes","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.leukres.2010.04.016_bib2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","article-title":"Chronic myelogenous leukemia: biology and therapy","volume":"131","author":"Faderl","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.leukres.2010.04.016_bib3","first-page":"413","article-title":"Case of hypertrophy of the spleen and liver in which death took place from suppuration of the blood","volume":"64","author":"Bennett","year":"1845","journal-title":"Edinb Med Surg J"},{"key":"10.1016\/j.leukres.2010.04.016_bib4","series-title":"Frorieps Notizen","author":"Virchow","year":"1845"},{"key":"10.1016\/j.leukres.2010.04.016_bib5","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"10.1016\/j.leukres.2010.04.016_bib6","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1073\/pnas.83.6.1807","article-title":"Heterogeneity of chromosome 22 breakpoint in Philadelphia-positive (Ph+) acute lymphocytic leukemia","volume":"83","author":"Erikson","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.leukres.2010.04.016_bib7","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2010.04.016_bib8","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib9","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","article-title":"New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance","volume":"145","author":"Kantarjian","year":"2006","journal-title":"Ann Intern Med"},{"issue":"April (17)","key":"10.1016\/j.leukres.2010.04.016_bib10","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"issue":"February (4)","key":"10.1016\/j.leukres.2010.04.016_bib11","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/1078-0432.CCR-06-2147","article-title":"Important therapeutic targets in chronic myelogenous leukemia","volume":"13","author":"Kantarjian","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2010.04.016_bib12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0950-3536(97)80004-2","article-title":"Signal transduction pathways involved in BCR-ABL transformation","volume":"10","author":"Sawyers","year":"1997","journal-title":"Baillieres Clin Haematol"},{"key":"10.1016\/j.leukres.2010.04.016_bib13","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis","volume":"103","author":"Calabretta","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib14","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/1097-0142(19821101)50:9<1683::AID-CNCR2820500904>3.0.CO;2-X","article-title":"Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia","volume":"50","author":"Bolin","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2010.04.016_bib15","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jnci\/89.21.1616","article-title":"Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists\u2019 Collaborative Group","volume":"89","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.leukres.2010.04.016_bib16","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","article-title":"Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders","volume":"98","author":"Bonifazi","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib17","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood.V86.3.906.906","article-title":"A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase","volume":"86","author":"Ohnishi","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib18","first-page":"1517","article-title":"An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology","volume":"94","author":"Silver","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib19","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib20","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra013339","article-title":"Imatinib mesylate\u2014a new oral targeted therapy","volume":"346","author":"Savage","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.04.016_bib21","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib22","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.leukres.2010.04.016_bib23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2010.04.016_bib24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.leukres.2010.04.016_bib25","first-page":"375","article-title":"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice","volume":"63","author":"Golas","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2010.04.016_bib26","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/1078-0432.CCR-06-2147","article-title":"Important therapeutic targets in chronic myelogenous leukemia","volume":"13","author":"Kantarjian","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2010.04.016_bib27","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1182\/blood.V99.10.3792","article-title":"Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation","volume":"99","author":"Holtz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib28","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.leukres.2010.04.016_bib29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1182\/blood-2003-08-2695","article-title":"Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia","volume":"104","author":"Legros","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib30","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1182\/blood-2003-08-2734","article-title":"Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy","volume":"103","author":"Kvasnicka","year":"2004","journal-title":"Blood"},{"issue":"January (2)","key":"10.1016\/j.leukres.2010.04.016_bib31","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood-2003-03-0975","article-title":"Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells","volume":"103","author":"Appel","year":"2004","journal-title":"Blood"},{"issue":"March (5)","key":"10.1016\/j.leukres.2010.04.016_bib32","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1182\/blood-2003-10-3475","article-title":"Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo","volume":"103","author":"Taieb","year":"2004","journal-title":"Blood"},{"issue":"March (5)","key":"10.1016\/j.leukres.2010.04.016_bib33","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1158\/1078-0432.CCR-04-1713","article-title":"Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt signaling pathways","volume":"11","author":"Appel","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"February (3)","key":"10.1016\/j.leukres.2010.04.016_bib34","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1182\/blood-2004-01-0027","article-title":"Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance","volume":"105","author":"Wang","year":"2005","journal-title":"Blood"},{"issue":"September (9)","key":"10.1016\/j.leukres.2010.04.016_bib35","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1038\/sj.leu.2404315","article-title":"Imatinib mesylate does not impair the immunogenicity of human myeloid blood dendritic cells","volume":"20","author":"Wehner","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.04.016_bib36","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.04.016_bib37","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia\u2014advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.04.016_bib38","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.04.016_bib39","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","article-title":"A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias","volume":"100","author":"Ottmann","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib40","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","article-title":"NS-187, a potent and selective dual Bcr-Abl\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia","volume":"106","author":"Kimura","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bbapap.2005.07.040","article-title":"Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia","volume":"1754","author":"Manley","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.leukres.2010.04.016_bib42","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","article-title":"AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL","volume":"94","author":"Weisberg","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.leukres.2010.04.016_bib43","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O\u2019Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2010.04.016_bib44","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrd2324","article-title":"Flying under the radar: the new wave of BCR-ABL inhibitors","volume":"6","author":"Quintas-Cardama","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.leukres.2010.04.016_bib45","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1182\/blood-2004-05-1851","article-title":"Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML","volume":"104","author":"O\u2019Hare","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib46","first-page":"4244","article-title":"Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases","volume":"62","author":"Wisniewski","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2010.04.016_bib47","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1073\/pnas.0408283102","article-title":"A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance","volume":"102","author":"Gumireddy","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.leukres.2010.04.016_bib48","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","article-title":"MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation","volume":"109","author":"Giles","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib49","unstructured":"O\u2019Brien S. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia, version 2.2010. http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/cml.pdf [accessed July 2009]."},{"key":"10.1016\/j.leukres.2010.04.016_bib50","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European Leukemia Net","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"October (15)","key":"10.1016\/j.leukres.2010.04.016_bib51","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.04.016_bib52","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.blre.2005.01.008","article-title":"Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia","volume":"20","author":"Hughes","year":"2006","journal-title":"Blood Rev"},{"issue":"November (11)","key":"10.1016\/j.leukres.2010.04.016_bib53","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2404388","article-title":"Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia","volume":"20","author":"Branford","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.04.016_bib54","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.04.016_bib55","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1158\/1078-0432.CCR-07-1112","article-title":"A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response","volume":"13","author":"Press","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2010.04.016_bib56","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","article-title":"Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression","volume":"26","author":"Khorashad","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.04.016_bib57","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.04.016_bib58","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1158\/0008-5472.CAN-05-0076","article-title":"Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia","volume":"65","author":"Barnes","year":"2005","journal-title":"Cancer Res"},{"issue":"January (1)","key":"10.1016\/j.leukres.2010.04.016_bib59","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.exphem.2009.10.003","article-title":"Constant BCR-ABL transcript level >or =0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis","volume":"38","author":"Polakova","year":"2010","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2010.04.016_bib60","first-page":"235","article-title":"The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia","volume":"91","author":"Wang","year":"2006","journal-title":"Haematologica"},{"issue":"September (13)","key":"10.1016\/j.leukres.2010.04.016_bib61","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1182\/blood-2008-08-173674","article-title":"Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib","volume":"114","author":"Press","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib62","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib63","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.04.016_bib64","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.04.016_bib65","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood-2003-01-0025","article-title":"Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha","volume":"102","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib66","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib67","series-title":"ASH Annual Meeting Abstracts, vol. 112","first-page":"335","author":"Cortes","year":"2008"},{"key":"10.1016\/j.leukres.2010.04.016_bib68","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF03195613","article-title":"Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene","volume":"49","author":"Baranska","year":"2008","journal-title":"J Appl Genet"},{"key":"10.1016\/j.leukres.2010.04.016_bib69","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.04.016_bib70","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib71","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","article-title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib","volume":"22","author":"Hochhaus","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.04.016_bib72","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib73","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1002\/cncr.24504","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2010.04.016_bib74","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib75","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1200\/JCO.2007.14.3339","article-title":"Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial","volume":"27","author":"Apperley","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.04.016_bib76","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib77","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/leu.2008.221","article-title":"Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase","volume":"22","author":"Cortes","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.04.016_bib78","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.04.016_bib79","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1200\/jco.2009.27.15_suppl.7007","article-title":"Dasatinib dose-optimization study in chronic phase chronic myeloid leukemia (CML-CP): three-year follow-up with dasatinib 100mg once daily and landmark analysis of cytogenetic response and progression-free survival (PFS)","volume":"27","author":"Stone","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.04.016_bib80","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1182\/blood-2008-11-186817","article-title":"Phase 3 study of dasatinib 140mg once daily versus 70mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up","volume":"113","author":"Kantarjian","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib81","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/jco.2008.26.15_suppl.7013","article-title":"SMOBe, efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP)","volume":"26","author":"Borthakur","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.04.016_bib82","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.04.016_bib83","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib84","doi-asserted-by":"crossref","first-page":"7029","DOI":"10.1200\/jco.2009.27.15_suppl.7029","article-title":"Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: longer follow-up results of a phase II study","volume":"27","author":"Kantarjian","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.04.016_bib85","doi-asserted-by":"crossref","first-page":"7057","DOI":"10.1200\/jco.2009.27.15_suppl.7057","article-title":"Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: longer follow-up results of a phase II study","volume":"27","author":"Le Coutre","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.04.016_bib86","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1200\/jco.2008.26.15_suppl.7017","article-title":"Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib","author":"Giles","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.04.016_bib87","doi-asserted-by":"crossref","first-page":"7074","DOI":"10.1200\/jco.2009.27.15_suppl.7074","article-title":"Molecular responses with nilotinib 800mg daily as first-line treatment of chronic myeloid leukemia in chronic phase: results of a phase II trial of the GIMEMA CML WP","volume":"27","author":"Martinelli","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.04.016_bib88","doi-asserted-by":"crossref","first-page":"669","DOI":"10.5858\/2006-130-669-IROAO","article-title":"Imatinib resistance: obstacles and opportunities","volume":"130","author":"Litzow","year":"2006","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.leukres.2010.04.016_bib89","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/asheducation-2007.1.371","article-title":"Medical management of CML","author":"Shah","year":"2007","journal-title":"Hematol Am Soc Hematol Educ Prog"},{"key":"10.1016\/j.leukres.2010.04.016_bib90","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1056\/NEJMp038130","article-title":"Minimal residual disease in chronic myeloid leukemia","volume":"349","author":"Lowenberg","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.04.016_bib91","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","article-title":"Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR-ABL","volume":"112","author":"Azam","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2010.04.016_bib92","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","article-title":"Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance","volume":"18","author":"Hochhaus","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.04.016_bib93","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2010.04.016_bib94","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib95","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib96","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.04.016_bib97","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.04.016_bib98","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2010.04.016_bib99","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.531","volume":"23","author":"Soverini","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.04.016_bib100","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00280-003-0741-6","article-title":"Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588","volume":"53","author":"le Coutre","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.leukres.2010.04.016_bib101","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients","volume":"22","author":"Peng","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.04.016_bib102","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib103","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib104","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.leukres.2008.07.015","article-title":"Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels","volume":"33","author":"Forrest","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2010.04.016_bib105","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","article-title":"Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia","volume":"25","author":"Darkow","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.leukres.2010.04.016_bib106","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1200\/jco.2008.26.15_suppl.6598","article-title":"Relationship between compliance, costs, hospitalizations for CML and GIST patients using imatinib mesylate [abstract]","volume":"26","author":"Halpern","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.04.016_bib107","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib108","doi-asserted-by":"crossref","first-page":"7394","DOI":"10.1158\/1078-0432.CCR-07-0346","article-title":"Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib","volume":"13","author":"van Erp","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2010.04.016_bib109","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00228-009-0772-y","article-title":"CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity","volume":"66","author":"Gr\u00e9en","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.leukres.2010.04.016_bib110","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/BF02353475","article-title":"Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans","volume":"24","author":"Wilkinson","year":"1996","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1016\/j.leukres.2010.04.016_bib111","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"eng","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.leukres.2010.04.016_bib112","first-page":"625","article-title":"Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients","volume":"9","author":"Gambacorti-Passerini","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2010.04.016_bib113","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.V99.2.713","article-title":"Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571","volume":"5","author":"J\u00f8rgensen","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib114","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","article-title":"Mechanisms of cancer drug resistance","volume":"53","author":"Gottesman","year":"2002","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.leukres.2010.04.016_bib115","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib116","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1182\/blood-2003-01-0083","article-title":"Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro","volume":"102","author":"Ferrao","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib117","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.leukres.2008.09.024","article-title":"Imatinib resistance in multidrug-resistant K562 human leukemic cells","volume":"33","author":"Assef","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2010.04.016_bib118","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cancergencyto.2005.01.015","article-title":"Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment","volume":"162","author":"Galimberti","year":"2005","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.leukres.2010.04.016_bib119","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.exphem.2009.02.006","article-title":"Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib","volume":"37","author":"Hatziieremia","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2010.04.016_bib120","doi-asserted-by":"crossref","first-page":"E118","DOI":"10.1208\/aapsj070112","article-title":"Role of the breast cancer resistance protein (ABCG2) in drug transport","volume":"7","author":"Mao","year":"2005","journal-title":"AAPS J"},{"key":"10.1016\/j.leukres.2010.04.016_bib121","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/sj.leu.2404638","article-title":"Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells","volume":"21","author":"Brendel","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.04.016_bib122","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1182\/blood-2004-04-1398","article-title":"Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2 drug pump","volume":"104","author":"Burger","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib123","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.leu.2404897","article-title":"Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2","volume":"22","author":"Shukla","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.04.016_bib124","doi-asserted-by":"crossref","first-page":"9809","DOI":"10.1158\/0008-5472.CAN-08-1008","article-title":"Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression","volume":"68","author":"Mahon","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2010.04.016_bib125","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bcp.2009.04.002","article-title":"Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1\/Pgp and ABCG2\/BCRP\/MXR transporters","volume":"78","author":"Tiwari","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.leukres.2010.04.016_bib126","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1124\/jpet.109.154781","article-title":"P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib","volume":"330","author":"Chen","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.leukres.2010.04.016_bib127","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-07-5095","article-title":"Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications","volume":"14","author":"Hiwase","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2010.04.016_bib128","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00280-007-0478-8","article-title":"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL","volume":"61","author":"Kamath","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.leukres.2010.04.016_bib129","doi-asserted-by":"crossref","first-page":"e7520","DOI":"10.1371\/journal.pone.0007520","article-title":"Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10)","volume":"4","author":"Shen","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2010.04.016_bib130","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib131","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib132","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4137\/117739010700200008","article-title":"NS-187 (INNO-406), a Bcr-Abl\/Lyn dual tyrosine kinase inhibitor","volume":"2","author":"Niwa","year":"2007","journal-title":"Anal Chem Insights"},{"key":"10.1016\/j.leukres.2010.04.016_bib133","doi-asserted-by":"crossref","first-page":"30907","DOI":"10.1074\/jbc.M605902200","article-title":"Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity","volume":"281","author":"Meyn","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2010.04.016_bib134","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib135","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1158\/0008-5472.CAN-03-1484","article-title":"Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia","volume":"64","author":"Donato","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2010.04.016_bib136","doi-asserted-by":"crossref","first-page":"34227","DOI":"10.1074\/jbc.M402290200","article-title":"A Bcr\/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2","volume":"279","author":"Dai","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2010.04.016_bib137","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djn188","article-title":"Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase","volume":"100","author":"Wu","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.leukres.2010.04.016_bib138","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.04.016_bib139","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","article-title":"In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells","volume":"66","author":"Puttini","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2010.04.016_bib140","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"issue":"April (16)","key":"10.1016\/j.leukres.2010.04.016_bib141","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1038\/onc.2008.29","article-title":"A brief introduction to FOXOlogy","volume":"27","author":"Burgering","year":"2008","journal-title":"Oncogene"},{"issue":"February (8)","key":"10.1016\/j.leukres.2010.04.016_bib142","doi-asserted-by":"crossref","first-page":"6411","DOI":"10.1074\/jbc.M211562200","article-title":"A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells","volume":"278","author":"Komatsu","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2010.04.016_bib143","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1182\/blood-2003-06-2042","article-title":"Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses","volume":"102","author":"Marin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib144","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/cncr.24066","article-title":"Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2010.04.016_bib145","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia","volume":"111","author":"Le Coutre","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.04.016_bib146","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/10428190601078464","article-title":"Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy","volume":"48","author":"Weisser","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"January (2)","key":"10.1016\/j.leukres.2010.04.016_bib147","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1365-2141.2003.04756.x","article-title":"Filgrastim-induced stem cell mobilization in chronic myeloid leukaemia patients during imatinib therapy: safety, feasibility and evidence for an efficient in vivo purging","volume":"124","author":"Kreuzer","year":"2004","journal-title":"Br J Haematol"},{"issue":"June (6)","key":"10.1016\/j.leukres.2010.04.016_bib148","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/leu.2008.376","article-title":"Sustained major molecular response in the absence of any antileukaemic therapy after dasatinib treatment and autologous peripheral blood stem cell transplantation in a patient with imatinib-resistant myeloblastic-phase chronic myeloid leukaemia","volume":"23","author":"Rea","year":"2009","journal-title":"Leukemia"},{"issue":"Suppl. 2","key":"10.1016\/j.leukres.2010.04.016_bib149","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.3816\/CLM.2007.s.006","article-title":"Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia","volume":"7","author":"Mughal","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"issue":"January (7280)","key":"10.1016\/j.leukres.2010.04.016_bib150","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nature08675","article-title":"Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors","volume":"463","author":"Zhang","year":"2010","journal-title":"Nature"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610002365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610002365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T02:24:23Z","timestamp":1635474263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212610002365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":150,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0145212610002365"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2010.04.016","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}